These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 15377438)
1. Comparing two arsenic trioxide administration methods in APL therapy. Zhou J; Meng R; Yang BF Chin Med J (Engl); 2004 Sep; 117(9):1411-3. PubMed ID: 15377438 [No Abstract] [Full Text] [Related]
2. Hyperleukocytosis from arsenic trioxide. Levy M; Wofford MM; Powell BL; McLean TW Pediatr Blood Cancer; 2008 Jun; 50(6):1265-7. PubMed ID: 18300308 [TBL] [Abstract][Full Text] [Related]
3. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia. Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432 [No Abstract] [Full Text] [Related]
4. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia]. Lengfelder E; Schultheis B; Büchner T; Hehlmann R Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223 [No Abstract] [Full Text] [Related]
5. Non-lethal bone marrow necrosis under first-line arsenic trioxide therapy in acute promyelocytic leukaemia. Ianotto JC; Tempescul A; Eveillard JR; Charles F; Berthou C Acta Haematol; 2010; 123(3):146-7. PubMed ID: 20134156 [No Abstract] [Full Text] [Related]
6. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. Douer D; Tallman MS J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332 [TBL] [Abstract][Full Text] [Related]
7. Arsenic trioxide induced acute flare-up of rheumatoid arthritis in a patient with APL. Naithani R; Mahapatra M; Kumar R; Kumar A; Agrawal N Ann Hematol; 2007 Feb; 86(2):151-2. PubMed ID: 17072614 [No Abstract] [Full Text] [Related]
13. Clinical usefulness of arsenic trioxide in the treatment of acute promyelocytic leukemia. Lo Coco F Haematologica; 2002 May; 87(5):452-3. PubMed ID: 12010655 [No Abstract] [Full Text] [Related]
14. [Coagulopathy and differentiation syndrome: the main complications of the initial treatment of acute promyelocytic leukemia]. Korístek Z; Zák P Vnitr Lek; 2008; 54(7-8):745-50. PubMed ID: 18780573 [TBL] [Abstract][Full Text] [Related]
15. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement. Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415 [TBL] [Abstract][Full Text] [Related]
16. Advances in management of acute promyelocytic leukemia with arsenic trioxide. Ma J Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904 [No Abstract] [Full Text] [Related]
17. Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia. Ducas RA; Seftel MD; Ducas J; Seifer C J R Coll Physicians Edinb; 2011 Jun; 41(2):117-8. PubMed ID: 21677914 [TBL] [Abstract][Full Text] [Related]
18. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. Barbey JT; Pezzullo JC; Soignet SL J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391 [TBL] [Abstract][Full Text] [Related]